Multiple-dose clinical pharmacology of the first-in-class CXCR7 antagonist ACT-1004-1239: Safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship in healthy subjects

Authors
Category Primary study
ConferenceEuropean Journal of Clinical Pharmacology
Year 2021
This article has no abstract
Epistemonikos ID: 0acfe2ceb90c5a81613d164bc27aaadd12786ad1
First added on: Apr 30, 2026